Cole

Abstract 3442: TP53 mutations in favorable risk WNT subtype medulloblastomas

*Cancer Research* 2011; 71(8 Suppl):3442

TP53 mutations in favorable-risk wnt/wingless-subtype medulloblastomas

*Journal of Clinical Oncology* 2011; 29(12):e344-e346

Rapid diagnosis of medulloblastoma molecular subgroups

*Clinical Cancer Research* 2011; 17(7):1883-1894

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival

*Pediatric Hematology and Oncology* 2011; 28(2):106-114

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival

*Pediatric Hematology and Oncology* 2011; 28(2):106-114

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

*Cancer Chemotherapy and Pharmacology* 2010; 66(4):807-812

Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose

*Pediatric Blood & Cancer* 2010; 54(7):983-989

Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate

*European Journal of Cancer* 2010; 46(10):1841-1847

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

*British Journal of Cancer* 2010; 102(6):1003-1009

High Frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma

*Clinical Cancer Research* 2010; 16(4):1108–1118